Skip to main content
. 2021 Dec 3;61(8):3257–3268. doi: 10.1093/rheumatology/keab905

Fig. 1.


Fig. 1

Integrated efficacy analysis of placebo-subtracted treatment effects

aFor patients with baseline LEI >0. bFor patients with baseline LDI >0. cFor patients with ≥3% body surface area psoriasis at baseline. LDI: Leeds Dactylitis Index; LEI: Leeds Enthesitis Index; NRS: numeric rating scale.